Thursday, 2 December 2021

Australia's most trusted
source of pharma news

Thursday, 02 December 2021

Lilly takes aim at Novo

Posted 24 November 2021 PM

Eli Lilly has taken Novo Nordisk to Medicines Australia over an alleged breach of the Code of Conduct for failing to "act promptly" to correct news articles that promoted the off-label use of Ozempic for weight loss/weight management in the mainstream media.

But according to an MA complaint outcome report, the claim was dismissed after investigation, with a finding that there was no breach of the code.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.